A Closer Look: Who Is The Biggest China Winner In Bayer/Merck Deal?
This article was originally published in PharmAsia News
Executive Summary
Bayer’s takeover of Merck’s consumer business should make it the largest OTC company in China. Meanwhile Merck will strengthen its cardiovascular position with access to Bayer’s Adempas (riociguat).